Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 36.4% in the 1st quarter, HoldingsChannel reports. The firm owned 6,149 shares of the medical technology company’s stock after buying an additional 1,641 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Hill-Rom were worth $619,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Stifel Financial Corp raised its position in shares of Hill-Rom by 18.1% during the 4th quarter. Stifel Financial Corp now owns 29,960 shares of the medical technology company’s stock worth $3,405,000 after purchasing an additional 4,599 shares during the last quarter. Swiss National Bank raised its position in shares of Hill-Rom by 1.9% during the 4th quarter. Swiss National Bank now owns 128,000 shares of the medical technology company’s stock worth $14,532,000 after purchasing an additional 2,400 shares during the last quarter. Csenge Advisory Group acquired a new position in shares of Hill-Rom during the 1st quarter worth approximately $242,000. Renaissance Technologies LLC raised its position in shares of Hill-Rom by 59.8% during the 4th quarter. Renaissance Technologies LLC now owns 378,616 shares of the medical technology company’s stock worth $42,984,000 after purchasing an additional 141,616 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Hill-Rom during the 4th quarter worth approximately $78,748,000. Hedge funds and other institutional investors own 85.90% of the company’s stock.

In other news, insider Amy M. Dodrill sold 3,189 shares of the business’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $110.00, for a total transaction of $350,790.00. Following the completion of the sale, the insider now directly owns 1,389 shares of the company’s stock, valued at approximately $152,790. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.65% of the stock is owned by insiders.

Several research analysts recently issued reports on HRC shares. UBS Group cut their price objective on Hill-Rom from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Barclays restated a “buy” rating and set a $125.00 price objective on shares of Hill-Rom in a research report on Tuesday, April 14th. Morgan Stanley cut their price target on Hill-Rom from $138.00 to $125.00 and set an “overweight” rating for the company in a report on Friday, March 27th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $131.00 price target on shares of Hill-Rom in a report on Friday, January 24th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $122.33.

Shares of HRC opened at $99.08 on Friday. The stock has a fifty day moving average of $107.38 and a two-hundred day moving average of $105.97. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.22 and a current ratio of 1.52. The company has a market capitalization of $6.59 billion, a PE ratio of 45.45, a price-to-earnings-growth ratio of 1.16 and a beta of 0.75. Hill-Rom Holdings, Inc. has a fifty-two week low of $72.29 and a fifty-two week high of $117.50.

Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, May 1st. The medical technology company reported $1.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.15 by $0.13. Hill-Rom had a return on equity of 22.60% and a net margin of 5.04%. The company had revenue of $723.20 million during the quarter, compared to the consensus estimate of $701.72 million. During the same period in the previous year, the firm posted $1.14 EPS. Hill-Rom’s revenue was up 1.3% on a year-over-year basis. As a group, equities research analysts forecast that Hill-Rom Holdings, Inc. will post 5.47 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Friday, June 19th will be paid a dividend of $0.22 per share. The ex-dividend date is Thursday, June 18th. This represents a $0.88 annualized dividend and a dividend yield of 0.89%. Hill-Rom’s dividend payout ratio is presently 17.32%.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Further Reading: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.